With SHS Capital’s investment in ESSERT GmbH, both companies are pooling their expertise in the pharmaceutical and life science sectors.
ESSERT GmbH was founded in Ubstadt-Weiher in 2012 and is a provider of scalable and flexible robot automation solutions. Right from the start, ESSERT strategically focused on production areas that are confronted with increasing product individualization. The company’s automation solutions are extremely flexible and can be quickly and easily retooled for new products.
In contrast to the competition, which relies on large machines with high throughput and low variation, ESSERT has a clear unique selling point with its highly specialized and individualized automation platform. As a result, the company has strong growth potential for the production challenges of the future and benefits from its many years of expertise in robotics, software and process competence.
Renowned customers from the highly regulated pharmaceutical and life science industry have been relying on ESSERT products for years. In particular, the so-called ESSERT MicroFactory, an intelligent and modular production platform, serves the high requirements of the customers very well and provides them with a suitable solution approach for the production challenges of the future, for example in the field of precision medicine.
“We are delighted to have SHS on board as an experienced investor with expertise. We will be able to benefit from SHS’ long-standing sector expertise and wide network in the healthcare sector to expand our customer base and further accelerate growth,” says ESSERT’s CEO Christopher Essert, who will continue to hold a significant stake in the company alongside SHS after the transaction.
“ESSERT is a prime example of the focus of our newly launched SHS VI fund generation. As an established, medium-sized company that anticipated the challenges of tomorrow’s production in the pharmaceutical and life science sectors early on, it is right on target with the current trend in the industry and has the opportunity to establish itself as a European market leader,” explains SHS partner Dr. Cornelius Maas.